Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Clovis Co-developing Companion Diagnostic for EGFR Mutations

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clovis Oncology and Roche today announced a partnership to develop an in vitro PCR-based companion diagnostic test for the identification of activating epidermal growth factor receptor mutations.

The assay, which will run on Roche's cobas 4800 system, is for the identification of mutations, including the EGFR T790M mutation, in patients with non-small cell lung cancer. The test will be for CO-1686, a compound currently in pre-clinical development for advanced NSCLC patients.

CO-1686 is designed to target and covalently bind to the activating T790M mutant forms of EGFR, and was licensed to Clovis from Avila Therapeutics.

"By incorporating a companion diagnostic during clinical and commercial development of CO-1686, we reinforce our commitment to focus development programs on specific subsets of cancer populations that are most likely to benefit from our targeted therapies," Patrick Mahaffy, president and CEO of Boulder, Col.-based Clovis, said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.